New chemo cocktail aims to wipe out stomach cancer cells before surgery
NCT ID NCT03773367
Summary
This study is testing if adding a third chemotherapy drug (irinotecan) to the standard two-drug combination improves outcomes for people with operable stomach or gastroesophageal junction cancer. Patients receive four cycles of the three-drug chemo before surgery and four more cycles after. The goal is to see if this more intensive approach kills more cancer cells and leads to better long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centrallasarettet i Växjö
Vaxjo, 352 34, Sweden
-
Karolinska University Hospital
Stockholm, 141 86, Sweden
-
Lund University Hospital
Lund, 221 85, Sweden
-
Oslo University Hospital, Ullevål Hospital
Oslo, 0450, Norway
Conditions
Explore the condition pages connected to this study.